MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at Association for Research in ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas, announced positive results from its Phase II ...
The Florida Times-Union

San Marcos Eye Doctors on Dry vs. Wet Macular Degeneration

Dr. Tory Prestera and Dr. Howard Guan share key differences between dry and wet macular degeneration, including common symptoms, causes, and treatment options. Dry macular degeneration is the more ...
LancasterOnline

Free webinar on age-related macular degeneration open to public via VisionCorps Monday

A local retinal surgeon and ophthalmology professor will speak about age-related macular degeneration during a free webinar ...
Ophthalmology Times

QA102 data suggest signal in intermediate dry AMD, but insignificant drusen volume change

According to MingMed Biotechnology, 1 the QA102-CS201 trial enrolled 150 patients with intermediate atrophic AMD and randomly ...

MingMed Biotechnology Co., Ltd: MingMed Biotechnology Presents Positive Phase II Data of Oral QA102 for the Treatment of Intermediate Age-Related Macular Degeneration (AMD) at ...

MingMed Biotechnology Co., Ltd, a biomedical firm focused on the discovery and development of novel therapeutics across multiple therapeutic areas ...

Positive Results from PulseSight’s Phase I Clinical Trial of PST-611 in Dry AMD/Geographic Atrophy Presented at ARVO 2026

PulseSight Therapeutics SAS, an ophthalmology clinical stage biotech company developing disruptive non-viral vectorized gene therapies with minimally-invasive delivery technology, has reported the ...
PharmaTimes

Pulsesight reports positive phase 1 data for PST‑611 in dry AMD

PulseSight Therapeutics has unveiled positive phase 1 results for PST‑611, its non‑viral gene therapy candidate for dry ...

Breakthrough Light Therapy Helping New Zealanders Regain Vision And Driving Independence

About Dr. James Leong: Dr. James Leong is an Oxford fellowship-trained consultant ophthalmologist specializing in medical retina, uveitis, and refractive cataract surgery. He is the founder of The Eye ...
The Manila Times

Beacon Therapeutics Annouces Presentations at the ARVO 2026 Annual Meeting

Beacon Therapeutics Holdings Limited (Beacon Therapeutics or the Company), a leading clinical-stage biotechnology company ...

Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting

Stealth BioTherapeutics (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving ...
Tribune Online on MSN

Problems with blurred vision

I am a 55-year-old civil servant. I recently noticed that I sometimes have blurred vision in the morning. Kindly let me know how to manage this. Emmanuel (by SMS)Managing blurred vision in an adult ...

Ocugen, Inc. Announces Closing for $130.0 Million of 6.75% Convertible Senior Notes

Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the closing of $130.0 million aggregate principal ...